Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Risk Control of Advanced Stage Tubo-ovarian or Primary Peritoneal Carcinoma Associated With Ovarian Carcinoma Risk-reducing Strategies, Including Fimbriectomy With Delayed Oophorectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer

NCT06726330 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT06726330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06726330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Risk Control of Advanced Stage Tubo-ovarian or Primary Peritoneal Carcinoma Associated With Ovarian Carcinoma Risk-reducing Strategies, Including Fimbriectomy With Delayed Oophorectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer
Lead sponsor
Centre Oscar Lambret
Phase
Not applicable
Overall status
Not yet recruiting
Start date
March 31, 2027
Completion date
March 31, 2071
Enrollment
1,100 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade serous carcinoma, primary peritoneal carcinoma, primary peritoneal carcinoma stage iii, primary peritoneal carcinoma stage iv, tubo-ovarian carcinoma